To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Not Applicable
Completed
- Registration Number
- CTRI/2010/091/002818
- Lead Sponsor
- AstraZeneca,Singapore Pte LtdAsia
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1279
Inclusion Criteria
Provision of written informed consent
- Patients age 20 years or older
- Histological or cytological confirmed advanced (stage IIIb/IV) NSCLC of adenohistology
- NSCLC treatment naïve
- Provision of cancer tissue or cytology sample (surgical specimen, biopsy sample, or cytology sample is acceptable).
Exclusion Criteria
- Involvement in the planning and/or conduct of the study (applies to both
AstraZeneca staff and/or staff at the study site)
- Previous enrolment in the present study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall EGFR mutation statusTimepoint: not applicable
- Secondary Outcome Measures
Name Time Method ilTimepoint: Nil